# Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

> **NCT01421524** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 271 (actual)

## Conditions studied

- Multiple Myeloma
- Lymphoma, Large B-Cell, Diffuse
- Pleiotropic Pathway Modifier
- Glioblastoma
- Lymphoma
- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** CC-122
- **DRUG:** CC-122
- **DRUG:** CC-122
- **DRUG:** CC-122

## Key facts

- **NCT ID:** NCT01421524
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-12
- **Primary completion:** 2023-11-21
- **Final completion:** 2023-11-21
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421524, "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01421524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*